Equillium Announces Poster Presentation at the Annual Meeting of The American Association of Immunologists
15 Maggio 2023 - 2:00PM
Business Wire
EQ102 selectively blocks IL-15 and IL-21
signaling while preserving signaling of other gamma chain family
members
Data suggest that selective blockade of IL-15
and IL-21 inhibits the synergistic signaling that mediates NK and T
cell responses in multiple immune disorders including celiac
disease
Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology
company leveraging a deep understanding of immunobiology to develop
novel therapeutics to treat severe autoimmune and inflammatory
disorders with high unmet medical need, today announced a poster
was presented over the weekend at IMMUNOLOGY2023, the annual
meeting of The American Association of Immunologists. The meetings
are taking place at the Walter E. Washington Convention center in
Washington, DC, May 11 – 15.
“We know that signaling of IL-15 and IL-21 is important in
driving T and NK cell responses and that each promote cytolytic
activity and interferon gamma production, but that blocking only
one of these cytokines is unlikely to improve disease outcome,”
said Dr. Cherie Ng, vice president of research at Equillium.
“Equillium is developing EQ102 to selectively and synergistically
block both IL-15 and IL-21 signaling, without affecting other gamma
chain family members. We believe this selective blockade could be
effective in treating celiac disease, known to be driven by
elevated levels of IL-15 and IL-21 that drive the T and B cell
responses culminating in tissue damage in these patients.”
Details of EQ102 Data Presented Title: γc receptor
antagonist, EQ102, prevents the NK and T cell-mediated responses
driven by IL-15 and IL-21 Presenting Author: Phoi Tiet,
Senior Research Associate, Equillium, Inc. Presentation
Type: Poster Session Poster Number: P854 Session
Title: Molecular Mechanisms of Cytokine Function
Key Highlights, Summaries & Conclusions from
Presentation:
- Synergistic signaling of IL-15 and IL-21 is important in
driving pathogenic T and NK cell responses in multiple inflammatory
diseases.
- IL-15 and IL-21 each promote cytolytic activity and IFNγ
production but can also synergistically enhance the function of
other cytotoxic cytokines. Consequently, blockade of only IL-15 or
only IL-21 is not likely to improve disease outcome in pathologic
environments.
- EQ102 is a multi-cytokine inhibitor that selectively blocks
IL-15 and IL-21 signaling while preserving signaling of other γc
family members.
- Co-stimulation of IL-15 and IL-21 enhanced proliferation,
activation, and IFNγ, Granzyme A, Granzyme B and Perforin
production above single cytokine conditions and EQ102 treatment
effectively inhibits the IL-15/IL-21 co-stimulatory cytolytic
responses of these cell populations.
- Results suggest that selective blockade of IL-15 and IL-21 by
EQ102 inhibits the synergistic signaling that mediates NK and T
cell responses in multiple immune disorders.
EQ102 has been shown to inhibit both IL-15 and IL-21 induced
signaling pathways in celiac patient-derived intraepithelial
cytotoxic T-Lymphocytes and key genes for tissue destruction in
patient-derived organoid cultures. Similarly, in pre-clinical
studies, EQ102 has demonstrated the prevention of intestinal tissue
damage in a humanized mouse model of gastrointestinal
inflammation.
About Multi-Cytokine Platform and EQ101 & EQ102
Our proprietary multi-cytokine platform generates rationally
designed composite peptides that selectively block key cytokines at
the shared receptor level targeting pathogenic cytokine
redundancies and synergies while preserving non-pathogenic
signaling. This approach is expected to avoid the broad
immuno-suppression and off-target safety liabilities that may be
associated with other therapeutic classes, such as Janus kinase
inhibitors. Many immune-mediated diseases are driven by the same
combination of dysregulated cytokines, and we believe identifying
the key cytokines for these diseases will allow us to target and
develop customized treatment strategies for multiple autoimmune and
inflammatory diseases.
Current platform assets include EQ101, a first-in-class,
selective, tri-specific inhibitor of IL-2, IL-9 and IL-15, and
EQ102, a first-in-class, selective, bi-specific inhibitor of IL-15
and IL-21.
About Equillium
Equillium is a clinical-stage biotechnology company leveraging a
deep understanding of immunobiology to develop novel therapeutics
to treat severe autoimmune and inflammatory disorders with high
unmet medical need. The company’s pipeline consists of the
following novel first-in-class immunomodulatory assets targeting
immuno-inflammatory pathways. EQ101: a tri-specific cytokine
inhibitor that selectively targets IL-2, IL-9, and IL-15; currently
under evaluation in a Phase 2 proof-of-concept clinical study of
patients with alopecia areata. EQ102: a bi-specific cytokine
inhibitor that selectively targets IL-15 and IL-21; currently under
evaluation in a Phase 1 first-in-human clinical study to include
healthy volunteers and celiac disease patients. Itolizumab: a
monoclonal antibody that targets the CD6-ALCAM signaling pathway
which plays a central role in the modulation of effector T cells;
currently under evaluation in a Phase 3 clinical study of patients
with acute graft-versus-host disease (aGVHD) and a Phase 1b
clinical study of patients with lupus/lupus nephritis. Equillium
acquired rights to itolizumab through an exclusive partnership with
Biocon Limited and has entered a strategic partnership with Ono
Pharmaceutical Co., Ltd. for the development and commercialization
of itolizumab under an option and asset purchase agreement.
For more information, visit www.equilliumbio.com.
Forward Looking Statements
Statements contained in this press release regarding matters
that are not historical facts are "forward-looking statements"
within the meaning of the Private Securities Litigation Reform Act
of 1995. Forward-looking statements may be identified by the use of
words such as "anticipate", "believe", “could”, “continue”,
"expect", "estimate", “may”, "plan", "outlook", “future” and
"project" and other similar expressions that predict or indicate
future events or trends or that are not statements of historical
matters. Because such statements are subject to risks and
uncertainties, many of which are outside of Equillium’s control,
actual results may differ materially from those expressed or
implied by such forward-looking statements. Such statements
include, but are not limited to statements regarding the benefit of
treating patients with celiac disease with EQ102 and Equillium’s
plans for developing EQ102. Risks that contribute to the uncertain
nature of the forward-looking statements include: Equillium’s
ability to execute its plans and strategies; risks related to
performing clinical studies; whether the results from clinical
studies will validate and support the safety and efficacy of
Equillium’s product candidates. These and other risks and
uncertainties are described more fully under the caption "Risk
Factors" and elsewhere in Equillium's filings and reports, which
may be accessed for free by visiting the Securities and Exchange
Commission’s website at www.sec.gov and on Equillium’s website
under the heading “Investors.” Investors should take such risks
into account and should not rely on forward-looking statements when
making investment decisions. All forward-looking statements
contained in this press release speak only as of the date on which
they were made. Equillium undertakes no obligation to update such
statements to reflect events that occur or circumstances that exist
after the date on which they were made, except as required by
law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230515005157/en/
Investor & Media Contact Equillium, Inc. Michael
Moore Vice President, Investor Relations Officer & Head of
Corporate Communications 619-302-4431 ir@equilliumbio.com
Grafico Azioni Equillium (NASDAQ:EQ)
Storico
Da Apr 2024 a Mag 2024
Grafico Azioni Equillium (NASDAQ:EQ)
Storico
Da Mag 2023 a Mag 2024